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Introduction: Assessment of cellulitis severity in the
emergency department (ED) setting is problematic.
Given the lack of research performed to describe the
epidemiology and management of cellulitis, it is
unsurprising that heterogeneous antibiotic prescribing
and poor adherence to guidelines is common. It has
been shown that up to 20.5% of ED patients with
cellulitis require either a change in route or dose of the
initially prescribed antibiotic regimen. The current
treatment failure rate for empirically prescribed oral
antibiotic therapy in Irish EDs is unknown. The
association of patient risk factors with treatment failure
has not been described in our setting. Lower
prevalence of community-acquired methicillin-resistant
Staphylococcus aureus-associated infection, differing
antibiotic prescribing preferences and varying
availability of outpatient intravenous therapy
programmes may result in different rates of empiric
antibiotic treatment failure from those previously
described.
Methods and analysis: Consecutive ED patients
with cellulitis will be enrolled on a 24/7 basis from 3
Irish EDs. A prespecified set of clinical variables will be
measured on each patient discharged on empiric oral
antibiotic therapy. A second independent study
recruiter will assess at least 10% of cases for each of
the predictor variables. Follow-up by telephone call will
occur at 14 days for all discharged patients where
measurement of the primary outcome will occur. Our
primary outcome is treatment failure, defined as a
change in route of antibiotic administration from oral to
intravenous antibiotic. Our secondary outcome is
change in dose or type of prescribed antibiotic. A
cohort of approximately 152 patients is required to
estimate the proportion of patients failing oral antibiotic
treatment with a margin of error of 0.05 around the
estimate.
Ethics and dissemination: Full ethics approval has
been granted. An integrated dissemination plan,
involving diverse clinical specialties and enrolled
patients, is described.
Trial registration number: NCT 02230813.
INTRODUCTION
Definition and epidemiology of cellulitis
Cellulitis is an infectious process of the dermal
and subdermal tissues that is of variable pres-
entation, aetiology and severity.1 Although
necrotising fasciitis and sepsis may develop in
a minority, most patients have a low risk of
complications.2 However, cellulitis and other
skin and soft tissue infections (SSTIs) repre-
sent a signiﬁcant disease burden, accounting
for between 1.5% and 3% of emergency
department (ED) attendances in Britain3 and
North America.4 5 Cellulitis is a term that is
often used interchangeably with erysipelas6
and for the purposes of this research proposal,
both entities will be considered synonymous
with the same disease.
Statement of the problem in the ED setting
Empirically prescribed antibiotic therapy for
cellulitis and other SSTIs varies signiﬁcantly in
choice, route and duration of therapy among
emergency physicians (EPs)4 and hospitalists,1
who adhere poorly to published guidelines.4 7
Furthermore, what guidelines do exist have
practically all been derived by expert consen-
sus3 8–11 or in cohorts of admitted hospital
inpatients. In a recent study of a commonly
used guideline in the UK, the Clinical
Resource Efﬁciency Support Team (CREST)
guideline,3 it was shown that over 50% of
patients suitable for oral antibiotic therapy
based on guideline classiﬁcation were actually
prescribed intravenous therapy.7 Two other
studies have examined the association between
predictor variables and failure of empirically
prescribed ED antibiotic therapy.12 13 Both
found that between 18.7% and 20.5% of ED
patients prescribed antibiotics subsequently
required either admission to hospital, change
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from oral to intravenous therapy or change in the type of
oral or intravenous antibiotic therapy prescribed. However,
both studies were performed in Canada where the
prevalence of community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA)-associated SSTI is high.14–
16 Furthermore, they assessed treatment failure in patients
receiving intravenous and oral antibiotic therapy in the ED
setting, which may not be applicable to settings without
developed outpatient intravenous therapy programmes.
The treatment failure rate of initially prescribed oral
antibiotic therapy in the ED setting in Ireland is
unknown. Furthermore, the association between patient
predictor variables and treatment failure has not been
described in our setting. The ﬁndings of this pilot study
will enable us to assess the feasibility of developing a
clinical prediction rule (CPR) so that a more evidence-
based approach to disposal of ED patients to oral or
intravenous antibiotic therapy can be developed. CPRs
are clinical tools that quantify the contribution of the
patient’s history, physical examination and diagnostic
tests and assist in the stratiﬁcation of patients according
to the probability of having a target disorder.17 They are
designed to reduce clinical uncertainty in an outcome
by assessing the strength of association between the risk
of the outcome occurring and baseline characteristics.18
Objectives
The primary aim of this study is to identify the treatment
failure rate of empirically prescribed oral antibiotic
therapy for ED patients discharged with cellulitis.
Treatment failure is deﬁned as a change in route of anti-
biotic administration from oral to intravenous antibiotic.
Speciﬁc objectives are:
1. To pilot a standardised clinical assessment for
patients with cellulitis, incorporating variables from
medical history, clinical examination and investiga-
tion, including a pain numerical rating scale and
physician-reported assessment scale;
2. To use this assessment in tandem with current clin-
ical assessment of patients with cellulitis;
3. To determine the treatment failure rate, the
loss-to-follow-up rate and the proportion of eligible
patients who enrol in the study;
4. To investigate the relationship between patient risk
factors and treatment failure;
5. To evaluate reasons why patients are not eligible in
order to determine if eligibility criteria need to be
changed for the full-scale trial;
6. To assess interobserver reliability.
METHODS AND ANALYSIS
We will conduct a prospective cohort study to enrol ED
patients with cellulitis from three hospitals (Beaumont
Hospital (BH), Connolly Hospital Blanchardstown and
Mater Misericordiae University Hospital (MMUH)) in
Dublin, Ireland. The combined annual ED patient
attendance volume is approximately 150 000. See online
supplementary material for deﬁnitions relevant to study
design.
Study population
Consecutive adult patients aged >16 years attending the
study EDs with cellulitis will be considered eligible for
recruitment to the study. Only those patients deemed
suitable for oral antibiotic therapy and planned for dis-
charge will be recruited to the study. Patients will be
recruited on a 24/7, round-the-clock basis. Cellulitis may
arise de novo, or from a recognised cause such as a
wound, abscess or ulcer. In order to generate an exter-
nally valid CPR, we will include all patients attending the
ED with cellulitis, including those who may have already
been started on oral antibiotics.
Inclusion criteria
Patient eligibility will be determined by the treating EP
based on the following inclusion criteria:
1. Age >16 years
2. Appearance of typical area of erythema over any
body part excluding the perineum, within the pre-
ceding 5 days with any two of the following signs:
A. Increased warmth over affected area
B. Swelling of affected area
C. Pain over affected area
3. Regional lymphadenopathy
4. Suitable for treatment with ﬂucloxacillin monother-
apy (500 mg–1 g four times daily) or a suitable alter-
native for penicillin-allergic patients as listed in the
local prescribing guidelines.
We will include patients with cellulitis secondary to
abscess provided that there is evidence of coexisting cel-
lulitis. Standard therapy for abscess is permitted includ-
ing incision and drainage, irrigation and packing.
Exclusion criteria
Respondents meeting any of the following criteria will
be excluded from the study:
1. Clinical requirement for intravenous antibiotics as
decided by the treating clinician;
2. Age less than 16 years;
3. No telephone or access to a telephone;
4. Abscess alone without coexisting signs of cellulitis;
5. Mammalian bite wounds;
6. Infected diabetic foot ulcer;
7. Necrotising soft tissue infections;
8. Perineal cellulitis (increased risk of Fournier’s
gangrene);
9. Suspected septic arthritis or osteomyelitis;
10. Decubitus ulcers;
11. Bilateral cellulitis (as this entity rarely exists);
12. Acute lipodermatosclerosis;
13. Acute dermatitis;
14. Venous stasis dermatitis;
15. Deep vein thrombosis;
16. Pregnancy;
17. Cognitive impairment;
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18. Any patient who through language barrier or dimin-
ished capacity is unable to understand the scope of
the study.
Patient assessment
Patients will be recruited by EPs and advanced nurse
practitioners (ANPs) in emergency medicine (EM),
both of whom are required to have at least 2 years post-
graduate experience in EM. We will explicitly advise
treating EPs or ANPs (‘ﬁrst study recruiters’) not to alter
their patient care for this study, but to continue with
usual care. Suitable patients meeting the prespeciﬁed
inclusion criteria will be invited to participate in the
study by the ﬁrst study recruiter. An information leaﬂet
will be given to them to read. A verbal explanation of
the study aims and procedure will also be conveyed.
After allowing the patient time to read the study patient
information leaﬂet (PIL), informed written consent will
be obtained from the patient.
Consenting patients will be given a study questionnaire
to complete. All study co-investigators and two layper-
sons reviewed this questionnaire for ease of reading.
The ﬁrst study recruiter will complete the listed pre-
dictor variables in a standardised, closed-response case
report form (CRF) by interview and examination of the
patient (see online supplementary material). Deﬁnitions
for each of the predictor variables will be made available
with the CRF. Any queries that may arise during comple-
tion of the questionnaire will be addressed at this time.
When feasible, a second EP or ANP (‘second study
recruiter’), blinded to the ﬁrst study recruiter’s assess-
ment will examine the patient and record the presence
of predictor variables. After assessment, the second
study recruiter will give their opinion as to whether they
would recommend oral or intravenous antibiotic therapy
for the patient. The second study recruiter must also
have at least 2 years postgraduate experience in EM and
will be asked to remain independent of the ﬁrst recrui-
ter’s patient assessment and ﬁnal decision for oral anti-
biotic therapy. At least 10% of all patient assessments
will be completed by a second study recruiter.
In order to ensure standardised data collection all
enrolling EPs and ANPs will be provided with a 30 min
individual training session regarding the study proce-
dures. Paper CRFs will be completed at the patient
bedside separately to their medical notes. ED clinical
records will also be completed in the standard fashion.
General practitioner (GP) contact details will be
recorded at the time of consent and patients will be
asked to permit the investigators to discuss their clinical
course with their GP and to access their healthcare
records in order to complete the case report form.
Quality assurance
Throughout the duration of the study, the completeness
of data collection and compliance with patient enrol-
ment will be quality assured. Follow-up of missed enrol-
ments will be achieved by cross-referencing ED
discharged patients with cellulitis from each participat-
ing ED’s patient database. Study recruiters will be given
regular feedback regarding the quality and complete-
ness of their data collection.
Selection of variables
The variables selected for assessment in the study were
chosen based on two observational studies,19 20 a litera-
ture review and input from all study investigators. The
number of variables collected was limited to ensure efﬁ-
cient completion of the data forms in the context of
usual patient care by study recruiters. The variables to
be collected are summarised in box 1.
Patient allocation
Patients will be discharged on a 7–14 day course of an
oral antibiotic recommended by the local hospital pre-
scribing guideline, which in the case of patients not





Pre-emergency department antibiotic therapy duration (in days)*
Level of pain in affected area (validated numerical scale)*
Rigors or self-reported fever*
Medical history
Chronic underlying comorbidity (eg, chronic kidney or liver
disease, chronic heart failure)
Body mass index calculated by weight/height2*
Previous episode of cellulitis in same area (yes/no)*
Peripheral vascular disease
Previous surgery to affected area*




Intravenous drug use (yes/no)
Heart rate (bpm)
Temperature (°C)
Systolic blood pressure (mm/Hg)
Respiratory rate (breaths/min)
Oxygen saturation on room air (%)
Level of awareness (Alert, Voice, Pain, Unresponsive (AVPU)
scale)
Capillary blood glucose (mmol/L)
C reactive protein (mmol/L)
White cell count (mmol/L)
Local clinical variables
Maximum diameter of infection (cm)
Ulcer (yes/no)
Wound (surgical or traumatic) (yes/no)
Athletes’ foot (interdigital skin breakdown/exudate in >1 web
space) (yes/no)
Fungal nail infection in affected leg if applicable
Skin breakdown due to underlying skin condition
Chronic limb oedema, including lymphoedema in affected limb
(yes/no)
*Assessed on patient questionnaire.
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allergic to penicillin in the participating EDs, is ﬂucloxa-
cillin 500 mg–1 g four times a day. Patients allergic to
penicillin will be treated according to local hospital pre-
scribing policy, which in each of the study sites recom-
mends either doxycycline, clindamycin or erythromycin.
Currently, the standard treatment is to discharge the
patient to the care of their GP. Patients enrolled will be
speciﬁcally asked to return to the treating ED for review
if their symptoms deteriorate while on oral antibiotic
treatment.
Patient follow-up
All patients will be consented for follow-up by telephone
contact at 14 days after the initial ED visit.
At this telephone review patients will be asked:
1. Whether their symptoms improved with oral anti-
biotic treatment;
2. Whether they re-presented to a healthcare setting for
a change in antibiotic drug, dose or route of
administration;
3. How they have felt since their last visit, with a descrip-
tion of any adverse events;
4. Whether they have had to change their antibiotic
due to side effects such as diarrhoea, nausea, vomit-
ing or thrush;
5. Whether they wish to receive the ﬁnal study results.
For patients who are not contactable by telephone at
day 14, consent will be obtained for their GP to be con-
tacted instead. Their GP will be asked whether the
patient has attended for review or to a hospital within
the previous 14 days with symptoms of cellulitis. Patients
will be described as a ‘treatment response’ if their symp-
toms have improved and ‘treatment failure’ if they have
required a change from oral to intravenous antibiotic
therapy. If at telephone interview the patient describes
worsening infection but has not yet attended a health-
care setting for review, he/she will be advised to attend
their treating ED and recorded as a treatment failure.
We will also record our secondary outcomes at tele-
phone interview (change in prescribed oral antibiotics
to a different oral antibiotic, increased dose of pre-
scribed oral antibiotic).
Outcome measures
The primary outcome is treatment failure deﬁned as a
change in route of antibiotic administration from oral
antibiotic to intravenous antibiotic.
Secondary outcome measures are:
1. Treatment failure measured by change in prescribed
oral antibiotic to another oral antibiotic.
2. Treatment failure measured by the change in pre-
scribed dose of oral antibiotic to a higher dose of the
same antibiotic.
3. Assessment of interobserver reliability for the clinical
variables listed in box 1. This will be performed in at
least 10% of patients enrolled into the study by a
second recruiting clinician.
4. Assessment of the eligibility and loss-to-follow-up rate.
Data analysis
Assessment of treatment failure
For measurement of the primay outcome (treatment
failure rate), the number of patients who fail oral anti-
biotic treatment will be expressed as a percentage of the
total number of patients prescribed oral antibiotic treat-
ment. For the secondary outcome (change in dose or
type of prescribed antibiotic), the percentage of patients
whose oral antibiotic prescribed in the ED is changed to
another oral antibiotic, or whose dose of oral antibiotic
is changed to a higher dose of the same antibiotic, will
be calculated.
Univariate associations between the explanatory vari-
ables and treatment failure will also be examined. These
results will be expressed as ORs; values of >1 indicating
increased odds of failing oral antibiotic treatment and
values of <1 indicating decreased odds of failing oral
antibiotic treatment. Explanatory variables considered of
prior clinical importance or having a threshold p value
of ≤0.15 in the univariate analysis will be included in a
multivariable logistic regression model.
Interobserver agreement
At least 10% of all patient assessments will be completed
by a second study recruiter. The interobserver agree-
ment for each variable listed in table 1 will be assessed
by calculating the κ coefﬁcient along with 95% CIs. For
variables with three or more ordered categories a
weighted κ will be calculated. A variable will be deemed
to have an acceptable agreement if the κ coefﬁcient has
a value of at least 0.6.21
Feasibility
Feasibility will be assessed in terms of recruitment,
response rates, loss to follow-up and eligibility.
Sample size
The sample size of this pilot study has been estimated
based on determining the proportion of patients failing
oral antibiotic treatment. Using a 95% CI for the pro-
portion of patients failing oral antibiotic treatment, a
margin of error of 0.05 and an expected proportion of
10% based on an educated guess, and two recent
studies15 16 suggesting that at least 6.8%, and up to 20%
of ED patients with cellulitis fail initially prescribed anti-
biotic therapy, the required sample for the pilot study
would be at least 152 patients.
ETHICAL ISSUES AND DISSEMINATION PLAN
The study protocol has received Research and Ethics
Committee approval from each recruiting site for initi-
ation. In order to prevent the likelihood of an adverse
event such as the enrolment of a patient with sepsis, we
have not permitted junior doctors with less than 2 years
postgraduate experience in medicine or surgery to recruit
patients. We would hope that having a senior staff member
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see each patient prior to discharge should reduce the risk
of such an occurrence from happening.
Adverse events will be speciﬁcally enquired for at the
telephone interview. Although not an ideal medium for
patient assessment it will provide a method to address
patient concerns and provide advice. Patients will be
advised to attend the referring ED for review if there are
concerns. Patients will also be asked if they would like to
directly receive, via mail or email, the ﬁnal study results as
a lay summary and/or as the ﬁnally published manuscript.
Although this is a pilot study, we aim to use the ﬁnd-
ings of this study to inform a larger CPR derivation
project. As such, integrated knowledge management
with EPs, ANPs and patients will be crucial to the long-
term success of the study. We will present our ﬁndings at
national and international conferences and publish our
research ﬁndings in a reputable peer-reviewed journal.
Our research is of considerable relevance to primary
care, which directs a large proportion of cellulitis treat-
ment in the Irish community. To address this, we will
supply each referring GP with a letter informing them
of the inclusion of their patient in this study, and dissem-
inate our study results by publication in suitable primary
care literature and through regular educational meet-
ings. Our research study group is a collaboration
between the main specialties that manage cellulitis in
Ireland, namely primary care, EM and general surgery.
Limitations
The three study sites serve a population where the
endemic rate of CA-MRSA is low. As a result, the ﬁnd-
ings may not be generalisable to all settings. Since tele-
phone follow-up will be used, patient recall bias may be
introduced to the study. However, since telephone
follow-up of patients with skin infections has been previ-
ously used in a similar research study,13 and patients
with deteriorating symptoms will be instructed to
re-present to an ED for assessment, we believe this
method of patient follow-up is feasible.
DISCUSSION
The proposed study aims to identify the treatment failure
rate of empirically prescribed oral antibiotic therapy for
cellulitis in three Irish EDs. We will also examine the asso-
ciation between patient risk factors for cellulitis and treat-
ment failure. The ﬁndings of this pilot study will permit
this research group to assess sample size, and feasibility,
for a future, larger CPR derivation project.
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